Is depression a side effect of finasteride (Finestride)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Depression a Side Effect of Finasteride?

Depression is not listed as a documented adverse effect in the major clinical guidelines for finasteride, though decreased libido, erectile dysfunction, and decreased ejaculate volume are well-established side effects. However, emerging research evidence from the past several years suggests a potential association between finasteride use and depression/suicidality that warrants serious consideration when prescribing this medication.

What the Guidelines and FDA Label Say

The 2009 ASCO/AUA clinical practice guideline 1 comprehensively reviewed adverse events from finasteride in large randomized controlled trials and does not mention depression as a recognized side effect. The documented adverse effects include:

  • Sexual dysfunction: 2-4% increase in erectile dysfunction, decreased libido, and decreased ejaculate volume compared to placebo
  • Gynecomastia: 4.1% vs 2.4% in placebo (statistically significant)
  • Endocrine effects: breast tenderness and enlargement

The FDA drug label 2 similarly does not list depression as a side effect in its adverse reactions section. Post-marketing surveillance mentioned hypersensitivity reactions, testicular pain, and male breast cancer, but not psychiatric symptoms.

What Recent Research Evidence Shows

The evidence landscape has changed dramatically since those 2009 guidelines. Multiple recent studies paint a concerning picture:

Studies Supporting an Association:

A 2025 analytical review 3 found that concerns about depression from finasteride were raised as early as 2002, but there has been a two-decade delay in recognition. Between 2017-2023, four independent analyses of adverse event reporting systems and four healthcare database studies indicated significant increases in risk for depression, anxiety, and suicidal behavior with finasteride use.

A 2021 meta-analysis 4 found:

  • Pooled rate of depressive symptoms: 3.33% with finasteride vs 2.54% without (p < 0.0001)
  • Odds ratio of 2.14 (95% CI: 1.40-3.27) for depression with finasteride
  • Risk of suicidal ideation/behavior: 21.2% vs 14.0% (p < 0.0001)

A 2025 FAERS database analysis 5 detected no significant signals from 2006-2011, but found signals during 2013-2018 and 2019-2023. For example, suicidal ideation reporting was significantly elevated (ROR = 2.8 in 2013-2018; ROR = 5.0 in 2019-2023).

A prospective 2006 study 6 of 128 men with androgenetic alopecia found that finasteride treatment significantly increased both Beck Depression Inventory scores (p < 0.001) and HADS depression scores (p = 0.005) after just two months of treatment.

Studies Contradicting the Association:

A 2025 cohort study and Mendelian randomization analysis 7 found no significant association between finasteride use and depression or suicide in the UK Biobank cohort, even after adjusting for covariates.

A 2025 animal study 8 showed that chronic finasteride administration (21 days) in rats did not induce robust depression- or anxiety-like behavior, potentially due to adaptive responses in corticosterone levels.

Clinical Interpretation and Recommendation

The divergence between older guidelines and recent research creates a clinical dilemma, but the weight of recent human evidence—particularly the meta-analysis 4 and multiple pharmacovigilance studies 3, 5—suggests depression and suicidality are real risks that must be discussed with patients.

When Prescribing Finasteride:

You should explicitly counsel patients about the potential for depression and suicidal ideation, even though this is not in the official FDA labeling. Specifically:

  • Screen for baseline depression/anxiety before initiating treatment
  • Avoid or use extreme caution in patients with current depression, history of depression, or suicidal ideation
  • Warn patients that psychiatric symptoms can emerge during treatment and may persist after discontinuation (so-called "post-finasteride syndrome")
  • Monitor actively for mood changes, especially in the first 2-6 months of treatment
  • Consider the risk-benefit ratio carefully: For androgenetic alopecia (a cosmetic indication), the potential for depression and suicidality may outweigh benefits in many patients

Important Caveats:

The 2009 guidelines 1 noted that sexual dysfunction effects were "smaller than natural sources of variability" (mean difference of 3.21 points on a 0-100 scale). However, this does not apply to depression risk, which was not adequately studied in those trials.

The increase in reported psychiatric adverse events after 2012 5 may reflect increased awareness following recognition of "post-finasteride syndrome," but this does not negate the reality of the symptoms—it likely represents previously under-recognized and under-reported harm.

The precautionary principle applies here: When a medication for a cosmetic indication (hair loss) carries potential risks of depression and suicide, the burden should be on proving safety, not on accumulating more evidence of harm 3.

Related Questions

Can finasteride worsen depression in a patient taking Prozac (fluoxetine) for depression?
How much does finasteride increase the risk of depression?
How should I manage a 40-year-old man with androgenetic alopecia on finasteride for 10 years who remains depressed despite bupropion (Wellbutrin)?
Can finasteride cause suicidal thoughts or depression, and what monitoring or precautions are recommended?
Does finasteride interact with quetiapine?
How should a 4 mg intravenous dose of lorazepam be administered for seizures?
What is the appropriate management for burning and peeling skin associated with Depakote (valproic acid) use?
I am experiencing burning and peeling skin while taking carbamazepine; what steps should I take?
What is the differential diagnosis for pelvic pain in a 56-year-old woman?
In a patient undergoing alcohol detoxification who has lower‑extremity edema and ascites while taking furosemide (Lasix) 40 mg daily, with an elevated BUN/creatinine ratio and low bicarbonate, how should his diuretic regimen be optimized?
Given a 30-year-old Black male, 6'5", 320 lb, with normal kidney and liver function, hypertension on amlodipine, G6PD deficiency, recent GERD, elevated CK, positive ANA with speckled pattern and markedly elevated RNP antibodies, mild troponin elevation, an initially abnormal ECG but normal 12‑lead ECG, normal chest X‑ray, D‑dimer 215 ng/mL, and pending EMG and muscle biopsy, what is the most likely diagnosis and prognosis, and can he expect recovery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.